Prospective, multicenter, open-label study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induced by cirrhosis, diabetes mellitus and cardiotoxic treatments (bB-ECHO).
Researcher | Principal Investigator Heart Failure Research Group
To study the efficacy of esmolol in the early identification of cardiovascular alterations induced by cirrhosis, diabetes mellitus, and cardiotoxic treatments.
Esmolol is a drug used in routine medical practice for the treatment of cardiac arrhythmias or in serious situations where it is necessary to rapidly control arterial hypertension.
- Reference: bB-ECHO
- Start date: January 1, 2021
- End date: December 31, 2024
- Funder: Instituto de Salud Carlos III
- Nature of project: National
Need more information?
If you are interested in learning more about our research, please contact us